Pyronaridine
drugOn this page
Also known as MalaridinePironaridinaSID174006948PYRONARIDINE TETRAPHOSPHATE
Summary
Pyronaridine (CHEMBL35228) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including malaria and plasmodium falciparum malaria.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 6 conditions
- Clinical trials: 15
- Chemistry: 518 Da · C29H32ClN5O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL35228 |
| Name | Pyronaridine |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 107771 |
| Molecular formula | C29H32ClN5O2 |
| Molecular weight | 518 |
| InChIKey | DJUFPMUQJKWIJB-UHFFFAOYSA-N |
SMILES: COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CC(=C(C(=C4)CN5CCCC5)O)CN6CCCC6
IUPAC name: 4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
Also known as: Malaridine, Pironaridina, Pyronaridine, pyronaridine, SID174006948, PYRONARIDINE, PYRONARIDINE TETRAPHOSPHATE
Parent form; salt/anhydrous children: CHEMBL1398478, CHEMBL2095224
Patent coverage: 470 distinct patent families (1,475 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,449 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: DNA topoisomerase 2, Vasopressin V2 receptor, Neuronal acetylcholine receptor subunit alpha-4, Alpha-2C adrenergic receptor, Equilibrative nucleoside transporter 1, Progesterone receptor, Muscarinic acetylcholine receptor M2, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Prostaglandin G/H synthase 2.
Bioactivity
ChEMBL activities: 5 potent at pChembl ≥ 5 of 21 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| KCNH2 | 6.55 | AC50 | 280 | nM | CHEMBL_ACT_25118762 |
| P41001 | 5.26 | IC50 | 5500 | nM | CHEMBL_ACT_25828672 |
| PDE3A | 5.24 | AC50 | 5700 | nM | CHEMBL_ACT_25191321 |
| PTGS2 | 5.21 | AC50 | 6200 | nM | CHEMBL_ACT_25166781 |
| SLC6A2 | 5.09 | AC50 | 8100 | nM | CHEMBL_ACT_25145610 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| malaria | 3 | MONDO:0005136 | EFO:0001068 |
| Plasmodium falciparum malaria | 3 | MONDO:0005920 | EFO:0007444 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| urinary schistosomiasis | 2 | MONDO:0006001 | EFO:0007530 |
| atopic conjunctivitis | 2 | MONDO:0005642 | EFO:0007141 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 15.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 5 |
| PHASE3 | 3 |
| PHASE1 | 3 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03201770 | PHASE4 | COMPLETED | Cohort Event Monitoring Study of Pyramax® |
| NCT03726593 | PHASE4 | UNKNOWN | Drug Combinations of Atovaquone-Proguanil (AP) With ACT |
| NCT00422084 | PHASE3 | COMPLETED | Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients |
| NCT00440999 | PHASE3 | COMPLETED | Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria |
| NCT00541385 | PHASE3 | COMPLETED | Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients |
| NCT04049916 | PHASE2/PHASE3 | COMPLETED | Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission |
| NCT05441410 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults |
| NCT01594931 | PHASE2 | COMPLETED | Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria |
| NCT03814616 | PHASE2 | UNKNOWN | Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections |
| NCT05291390 | PHASE2 | UNKNOWN | Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) |
| NCT05689047 | PHASE2 | COMPLETED | Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1) |
| NCT05974267 | PHASE2 | COMPLETED | Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) |
| NCT01383109 | PHASE1 | COMPLETED | Human Mass Balance Study of Pyronaridine |
| NCT05160363 | PHASE1 | COMPLETED | A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate |
| NCT05287893 | PHASE1 | COMPLETED | Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).